CF
PACB icon

Corebridge Financial’s Pacific Biosciences PACB Stock Holding History

Corebridge Financial’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-134,010
Closed -$158K – 1955
2025
Q1 		$158K Sell
134,010
-1,985
-1% -$3.04K ﹤0.01% 2208
2024
Q4 		$249K Sell
135,995
-10,266
-7% -$20K ﹤0.01% 2052
2024
Q3 		$249K Sell
146,261
-902
-0.6% -$1.48K ﹤0.01% 2103
2024
Q2 		$202K Buy
+147,163
New +$297K ﹤0.01% 2188

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Corebridge Financial's PACB Position: Q2 2025 in Review

Corebridge Financial sold out of Pacific Biosciences (PACB) in Q2 2025, closing a stake of 134,010 shares — an estimated $158K sold.

Corebridge Financial first reported a position in PACB in Q2 2024 and held it in 4 quarters. The position peaked at $249K in Q4 2024. 207 funds tracked by Wall St. Rank hold PACB as of Q2 2025.

  • Corebridge Financial reported no remaining Pacific Biosciences position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 134,010 Pacific Biosciences shares in Q2 2025, an estimated $158K.
  • Corebridge Financial first reported a position in Pacific Biosciences in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Pacific Biosciences position peaked at $249K in Q4 2024.
  • 207 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.